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The knowledge that advanced age is a major risk factor for cardio-
vascular disease (CVD) has stimulated interest in cardiac aging. Un-
derstanding how the heart remodels with age can help us appreciate
why older individuals are more likely to acquire heart disease. Growing
evidence in both humans and animals shows that the heart exhibits
distinct structural and functional changes as a consequence of age.
These changes occur even in the absence of overt cardiovascular
disease and are often maladaptive. For example, atrial hypertrophy
and ﬁbrosis may increase susceptibility to atrial ﬁbrillation in older
adults. Age-dependent increases in left ventricular ﬁbrosis, stiffness,
and wall thickness promote diastolic dysfunction, predisposing to heart
failure with preserved ejection fraction. The inﬂuence of age on the
heart is evident at rest but is even more prominent during exercise.
There is also evidence for sex-speciﬁc variation in age-associated
remodelling. For instance, there is some evidence that the number
of ventricular myocytes declines with age through apoptosis in men
but not in women. This helps explain why older men are more likelyReceived for publication January 14, 2016. Accepted March 30, 2016.
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Sachant qu’un âge avance constitue en soi un important facteur de
risque de maladie cardiovasculaire (MCV), on s’interesse actuellement
de plus en plus au phenomène du vieillissement cardiaque. Une
meilleure comprehension des mecanismes du remodelage cardiaque
au ﬁl du temps pourrait aider à expliquer pourquoi les personnes
âgees sont plus susceptibles de souffrir de maladie du cœur. Des
donnees probantes croissantes, obtenues tant chez des modèles ani-
maux qu’humains, montrent que le cœur subit des modiﬁcations
structurelles et fonctionnelles precises au ﬁl des annees. Ces modiﬁ-
cations surviennent même en l’absence de MCV averee et sont sou-
vent la consequence d’une problematique adaptative. Par exemple,
l’hypertrophie et la ﬁbrose auriculaire peuvent accroître le risque de
ﬁbrillation auriculaire chez les adultes plus âges. De même, l’aug-
mentation liee à l’âge de la ﬁbrose, de la rigidite et de l’epaisseur de la
paroi ventriculaire gauche peut favoriser l’apparition d’une dysfonction
diastolique qui evoluera vers une insufﬁsance cardiaque sans alte-
ration de la fraction d’ejection ventriculaire gauche. Les effets de l’âgeThe incidence of cardiovascular disease (CVD) rises dramat-
ically with age in men and women. The idea that age itself is a
risk factor for the development of CVD has motivated interest
in the ﬁeld of cardiac aging. Growing clinical and experi-
mental evidence demonstrates that the aging process promotes
structural and functional remodelling of the heart, even in the
absence of overt CVD. Whether these age-related modiﬁca-
tions represent a disease phenotype is debated. However, these
changes do render the aging heart more susceptible to CVD,
as discussed in detail in this review.
This article reviews important structural modiﬁcations in
the aging heart at both the macroscopic and microscopiclevels. We also discuss the impact of age on heart function,
with emphasis on the pacemaker, the conduction system, the
atria, and the ventricles. Key molecular mechanisms involved,
including altered calcium homeostasis, dysregulation of the ß-
adrenergic and renin-angiotensin pathways, and mitochon-
drial dysfunction are also considered. Throughout the review,
we highlight male/female differences in cardiac aging. The
terms “age” and “aging” are used to refer to the effect of
chronological age on the heart, although we discuss emerging
evidence that biological age, measured as frailty, may exacer-
bate changes associated with cardiac aging.Age-Associated Changes in Cardiac Structure
Macroscopic changes associated with cardiac aging
Normal cardiac aging is characterized by structural
changes at both macroscopic and microscopic levels. Studies
in humans have shown that epicardial adipose tissue depo-
sition increases markedly with age.1 Calciﬁcation of speciﬁcn Cardiovascular Society. This is an open access article under the CC BY-NC-
than women to experience heart failure with reduced ejection fraction.
Emerging evidence from preclinical studies suggests that frailty rather
than chronological age promotes adverse cardiac remodelling. Mech-
anisms implicated in cardiac aging include impaired calcium handling,
excessive activation of the ß-adrenergic and renin-angiotensin sys-
tems, and mitochondrial dysfunction. Further research into cardiac
aging in both sexes is needed, because it may be possible to modify
disease treatment if the substrate upon which the disease ﬁrst de-
velops is better understood.
sur le cœur sont evidents au repos, mais plus encore à l’effort. Par
ailleurs, des donnees montrent que le remodelage cardiaque s’effec-
tue differemment en fonction du sexe. Par exemple, on sait desormais
que le mecanisme d’apoptose entraîne une diminution du nombre de
myocytes ventriculaires chez l’homme, mais pas chez la femme. Cela
explique pourquoi les hommes sont plus susceptibles que les femmes
de souffrir d’une insufﬁsance cardiaque avec reduction de la fraction
d’ejection ventriculaire gauche. Des donnees probantes recentes, is-
sues d’etudes precliniques, portent à croire que le remodelage car-
diaque pathologique serait plus fonction de la fragilite de l’organisme
que de l’âge chronologique de la personne. Parmi les mecanismes
pathologiques impliques dans le vieillissement cardiaque, on retrouve
notamment les alterations du metabolisme calcique, l’activation
excessive des systèmes ß-adrenergique et renine-angiotensine ainsi
que la dysfonction mitochondriale. Il faudra mener davantage de
recherches sur le vieillissement cardiaque chez l’homme et la femme,
car une meilleure comprehension des mecanismes sous-jacents per-
mettrait sans doute de mieux adapter les strategies de traitement des
MCV.
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Volume 32 2016regions, including the aortic valve leaﬂets, also occurs in
older adults.2 In addition, there are changes in the gross
morphologic structure of the heart. Atrial remodelling
characterized by larger atrial size and volume occurs,
although not until the eighth decade unless underlying
CVD is present.3 Left ventricular (LV) wall thickness in-
creases in healthy older adults, whereas LV systolic and
diastolic volumes decline with age in both sexes.4 Whether
LV mass is affected by age is controversial,4,5 although LV
mass-to-volume ratios increase with age in both men and
women. The major macroscopic changes in heart structure
with age are illustrated in Figure 1.
Cellular cardiac aging
Age-dependent cardiac remodelling also occurs at the
microscopic level. In humans, the number of sinoatrial node
(SAN) pacemaker cells declines markedly with age.6 There is
also some evidence that ventricular myocyte numbers may
decline with age and that this may be more prominent in
men than in women.7,8 The loss of myocytes may result
from apoptosis, necrosis, or autophagy (or a
combination),9-11 although limited regenerative ability of
stem cells also may contribute.12 Age-related cell loss can, in
theory, increase the mechanical burden on surviving myo-
cytes and lead to compensatory hypertrophy. Morphometric
analysis suggests that ventricular myocyte volume increases
with age and that this may be more pronounced in men
than in women.7,8 Still, the question of whether age-
dependent myocyte loss and hypertrophy occur at different
rates and through different mechanisms in male and female
hearts has not been ﬁrmly established, and additional studies
would be helpful in resolving this issue. Although the
number of cardiomyocytes may decline with age, there is
marked proliferation of cardiac ﬁbroblasts, the cells that
produce extracellular matrix and collagen.13 The accumu-
lation of collagen leads to interstitial ﬁbrosis in the atria,
SANs, and ventricles of older adults.6,14 Key microscopic
changes characteristic of cardiac aging are shown in Figure 1.
Both gross and cellular changes in heart structure with ageare believed to adversely affect myocardial function, as dis-
cussed in detail in the section Impact of Age on Cardiac
Function.
Animal models exhibit the major age-associated
structural changes seen in humans
Animal models have been used to explore many aspects of
cardiac aging. Rats and mice have a 50% mortality rate at 24
months of age,15 comparable to that in 85-year-old humans,16
so most studies use 24-month-old rodents to model human
aging. Many of the macroscopic changes characteristic of
aging human hearts also occur in older animals. For example,
epicardial fat deposition and aortic valve calciﬁcation are seen
in older animals.17,18 There is also evidence for atrial hyper-
trophy and dilatation in older rodents, and LV wall thickness
increases with age in older rats and mice.10,19,20
Microscopic changes observed in aging human hearts are
also seen in older animals. Whether the number of pacemaker
cells decreases with age in animals is unclear, but the
expression of ion channels involved in SAN function declines
with age in rats.21 Ventricular myocyte loss through apoptosis,
along with an increase in the cross-sectional area of surviving
cells, occurs in aging male nonhuman primates, although this
is not seen in older female nonhuman primates.22 There also
is a growing consensus that ventricular myocyte hypertrophy
(increased length, width, and cross-sectional area) occurs in
aging male rodents as well as in guinea pigs and rabbits.23
Whether ventricular myocyte hypertrophy occurs in myo-
cytes from female aging rodents is less clear because some
studies have reported increased cell length, width, and area,
whereas others have not.23-26 This suggests that both
concentric hypertrophy, associated with lateral growth of in-
dividual myocytes, and eccentric hypertrophy, linked to lon-
gitudinal cell growth, may occur in the aging male heart. As
with humans, additional studies that investigate whether age-
dependent myocyte loss and hypertrophy occur at the same
rates and through the same mechanisms in both sexes would
be interesting. Other age-dependent cellular changes reported
in aging rodents and in larger animals include ﬁbroblast
Figure 1. Major age-dependent changes in the structure of the heart at the macroscopic and microscopic levels. (A) Young adult heart. (B) Aged
heart. Compared with the younger adult heart, the aged heart exhibits gross structural changes, including epicardial fat deposition, calciﬁcation of
the aortic valve, atrial hypertrophy and dilatation, as well as hypertrophy of the left ventricle. Changes at the cellular level include the loss of
ventricular myocytes and hypertrophy of the remaining cells. There is also an increase in the number of ﬁbroblasts with age and a marked increase
in ﬁbrosis. Some of these age-dependent changes may be modiﬁed by factors such as sex and frailty, as discussed in the text. Illustration by
Monique Guilderson. Reproduced with permission of Maritime Medical Design and Monique Guilderson.
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both the atria and the ventricles.13,19,27 Key structural changes
linked to cardiac aging in humans and in animals are sum-
marized in Table 1 and illustrated in Figure 1.
Our group has explored the link between biological age,
measured as frailty, and age-dependent changes in the heart.
We developed a method to quantify frailty with a “frailty
index” based on the idea that health deﬁcits accumulate with
age.43,44 A frailty index score is obtained by counting the
deﬁcits in health in an individual and dividing by the total
number of potential deﬁcits to obtain a score between 0 (no
deﬁcits) and 1 (all possible deﬁcits). Our work has shown that
myocyte hypertrophy occurs predominantly in aged mice with
high frailty scores.43 By contrast, mice of the same age with
low frailty scores do not exhibit hypertrophy.43 Thus, some
aspects of age-dependent remodelling might be more closely
linked to biological age (frailty) than chronological age.Impact of Age on Cardiac Function
Many structural changes associated with normal aging are
maladaptive. For example, age-related increases in epicardial
adipose tissue are associated with a higher prevalence of
various CVDs,45 although whether pericardial adipose tissueincreases with age is unclear. This could be important, because
pericardial fat is a known risk factor for diseases such as atrial
ﬁbrillation, which is common in older adults.46 Calciﬁcation
of the aortic valve leaﬂets impairs their movement, which can
obstruct LV outﬂow and promote the development of heart
failure,2 especially in older men.28 The concept that age
adversely affects heart structure and predisposes elderly in-
dividuals to acquire heart disease has encouraged interest in
the effects of age on electrical and contractile function of the
heart.
Inﬂuence of age on pacemaker and cardiac conduction
processes
Heart rate (HR) is not affected by age in supine men and
women.47 There is also no difference in resting HRs be-
tween young adult and aged rodents of both sexes.48-50
However, HR increases less in older adults than in
younger adults when they move from a supine to a seated
position.47 This impaired ability to increase HR arises, in
part, because of the age-associated decline in responsiveness
to sympathetic stimulation,41 as discussed in the section
The Impact of Age on Heart Function During Exercise. A
decline in pacemaker cell number and reduced ion channel
Table 1. Clinical consequences of cardiac aging
Age-related change Consequences Sex difference
Aortic valve calciﬁcation2,18 Promotes heart failure2 More common in men28
Loss of SAN cells6
Y Expression SAN channels21
Lower HR6,21
Promotes bradycardias6,21
Unclear
[ Late diastolic ﬁlling4
Y Early diastolic ﬁlling5
[ Atrial contraction4
Atrial hypertrophy5
Unclear
Atrial hypertrophy5
Atrial ﬁbrosis6,29-31
Electrical remodelling of atria35
Increases susceptibility to atrial ﬁbrillation32,33 More prevalent in men34
Worse outcomes in women34
Fewer ventricular myocytes7,8,22
Myocyte hypertrophy7,8,22
Y Myocyte contraction23,24
Y Calcium transient23,24
Y Systolic function36
Promotes heart failure, especially HFrEF36 Cell loss and hypertrophy may be worse in men7,8,22
Systolic function worse in men36
[ LV wall thickness4,10,19
[ LV ﬁbrosis and stiffness6,13,14,20
Slowed calcium removal23
[ Diastolic calcium23
Slow passive LV ﬁlling10,37
Promotes diastolic dysfunction10,37
Predisposes toward HFpEF37,39
More prevalent in women36,38
Worse outcomes in men40
Y Sensitivity to b-adrenergic stimulation41 Impairs ability to [ HR and force in exercise May be more pronounced in men42
HR, heart rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; SAN, sinoatrial
node.
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contribute to lower HRs in older adults.6,21 Age-related
SAN dysfunction may help explain the development of
bradyarrhythmias and symptoms that require pacemaker
implantation in older adults.6,21 The cardiac conduction
system changes characteristically with age. Age-related
prolongation of the QRS complex, consistent with a slow-
ing of conduction, is seen in humans and animals.6,51
Animal studies demonstrate that reduced cell-to-cell con-
nections, mediated by lower expression of connexion-43,
slow conduction in the aging heart.51 These age-
dependent changes in conduction may promote dysrhyth-
mias in older adults.
Age-dependent atrial remodelling
In young adults, early LV ﬁlling occurs rapidly so that very
little ﬁlling is caused by atrial contraction later in diastole. By
contrast, slow early LV ﬁlling is a characteristic feature of the
aging heart, as discussed in more detail in the section Diastolic
Dysfunction. Slow LV ﬁlling increases diastolic ﬁlling pressure,
which results in atrial dilatation and hypertrophy.5 This en-
hances the force of atrial contraction and promotes late dia-
stolic ﬁlling to compensate for reduced ﬁlling early in
diastole.4 In consequence, the atria make a larger contribution
to ventricular ﬁlling in older adults than in younger adults.
Thus, attenuation of atrial contraction in diseases such as
atrial ﬁbrillation can markedly reduce diastolic volumes in
older individuals.5 This reduces cardiac output, which pre-
disposes older individuals toward the development of heart
failure.
Dilatation is not the only change in aging atria. Along
with the loss of SAN cells, there is a loss of atrial myocytes
and increased interstitial ﬁbrosis.6 Indeed, atrial ﬁbrosis in-
creases with age in both men and women.29,30 Atrial ﬁbrosis
also increases in older dogs, although whether this differs
between the sexes is unclear.31 Mechanisms implicated in
cardiac ﬁbrosis include chronic systemic activation of
the renin-angiotensin-aldosterone system, mitochondrialdysfunction, and generation of reactive oxygen species,14,52 as
discussed in the section Cellular Mechanisms of Dysfunction in
the Aging Heart.
Other studies have investigated age-dependent changes in
atrial electrophysiology. Most studies have used atrial myo-
cytes from patients with underlying CVD, and few have
examined individuals older than 70 years of age.35 Thus,
whether age inﬂuences the electrophysiological properties of
atrial myocytes from healthy older humans is not clear.
Studies in older animals have shown that right atrial myocytes
are depolarized, with longer action potentials than those in
younger animals.35 These changes in action potential conﬁg-
uration are associated with an increase in potassium currents,
although calcium currents in these cells decline with age.35
Together, age-related changes in ion channels, along with
atrial ﬁbrosis and hypertrophy, provide an ideal substrate for
the development of atrial ﬁbrillation, which is common in
older adults.32 There is evidence for a higher incidence of
atrial ﬁbrillation in men, although women often have worse
outcomes, including stroke and systemic embolization.34
Interestingly, susceptibility to atrial ﬁbrillation also increases
with age in mice, at least in male mice.33 Whether age-
dependent atrial remodelling differs between the sexes is not
yet clear, and additional studies are warranted.
Age and sex affect resting systolic function
Traditionally, measures of systolic function, including
stroke volume and ejection fraction, were said to be similar in
young and older adults at rest.47 More recent evidence in-
dicates that cardiac contractility is well preserved in women
but actually declines in men after age 50 years.53 Interestingly,
echocardiographic studies in animals support this view. Sys-
tolic function (stroke volume, ejection fraction) declines with
age in male rodents but not in female rodents.48-50,54,55
Corresponding changes occur at the cellular level. There is
some evidence from studies in both humans and animals that
the number of ventricular myocytes declines with age in the
male but not the female sex.7,8,22 Furthermore, our work in
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contract declines with age in male rodents more than in fe-
male rodents.24,25 We have also shown that reduced con-
tractile function in cells from male rodents is caused by an
age-dependent decline in peak calcium transients.24,25 These
ﬁndings are consistent with older men being more likely than
older women to experience heart failure with reduced ejection
fraction (HFrEF).36
Frailty also appears to affect contractile function in older
adults. We have found that cellular contractile depression
occurs in mice with the highest frailty scores, whereas those
with lower scores show little evidence of contractile
dysfunction.43 This is important because frailty is common
in older patients with heart failure, who experience worse
outcomes and higher mortality than do nonfrail patients of
the same age.56 That frailty predicts contractile dysfunction
better than does chronological age suggests that frailty may
predispose individuals toward the development of heart
failure.43
Diastolic dysfunction
Diastolic dysfunction, characterized by problems with
relaxation, is a hallmark of cardiac aging. In young adult
hearts, LV ﬁlling occurs early and rapidly as a consequence of
ventricular relaxation.5,47 By contrast, hearts from older in-
dividuals ﬁll with blood more slowly.5,47 Indeed, the rate of
LV ﬁlling in the early diastolic phase declines with age by the
sixth decade in both sexes.3 This age-dependent slowing of
relaxation in diastole may predispose the aging heart toward
heart failure with preserved ejection fraction, commonly
referred to as HFpEF.37,39 HFpEF is characterized by
increased wall thickness and diastolic dysfunction with little or
no reduction in ejection fraction.50,53 It is common in older
adults, although there appear to be important male/female
differences.36,38,40 Risk factors for HFpEF also differ between
the sexes, with factors such as myocardial ischemia being
important in men and hypertension playing a major role in
women.38 The increase in diastolic dysfunction with age is
signiﬁcant, because population aging has led to a growing
epidemic of HFpEF. Furthermore, although evidence-based
treatments can improve prognosis in HFrEF, there are no
current treatments for HFpEF.37,38
The increasing prevalence and lack of treatment options for
HFpEF has promoted interest in the determinants of age-
related diastolic dysfunction. Aging rodents of both sexes
exhibit slowed relaxation and diastolic
dysfunction.48-50,54,55,57 This suggests that underlying
mechanisms of potential relevance to humans can be inves-
tigated in animals. Several mechanisms have been implicated.
For example, increased ﬁbrosis is thought to increase ven-
tricular stiffness.13 This reduces ventricular compliance and
impairs passive ﬁlling of the left ventricle.37 The thicker less
distensible LV walls seen in older humans and animal hearts
also may contribute to the development of HFpEF.4,10,19 In
addition, increased myocyte stiffness, mediated by age-
dependent changes in the sarcomeric protein titin,
contribute to the increase in LV stiffness in HFpEF.58
Changes in intracellular calcium homeostasis have also been
implicated in the pathogenesis of HFpEF, as discussed in the
section Cellular Mechanisms of Dysfunction in the Aging Heart.The impact of age on cardiac function during exercise
The effects of cardiac aging are seen more clearly during
exercise when the heart must respond to stress. Although
resting HRs are not affected by age, the maximum HR ach-
ieved during exercise declines with age in both sexes.59
Reduced sensitivity of the myocardium to sympathetic stim-
ulation is implicated. Normally, activation of the sympathetic
nervous system during exercise releases catecholamines (eg,
noradrenaline, adrenaline) that activate b-adrenergic receptors
in the heart to increase the rate and force of contraction.
However, the evidence that the heart’s responsiveness to
b-adrenergic stimulation declines with age in humans and
animals is strong,41,42,60-62 as discussed in the section Intra-
cellular Calcium Homeostasis. Interestingly, 1 study in
nonhuman primates found that in vivo responses to
b-adrenergic receptor stimulation declined with age in the
male but not the female sex.42 Still, whether responsiveness to
catecholamines differs between the sexes is unclear, because
most clinical/preclinical studies have either focused on older
male animals or have not investigated sex differences.
Because HR is a key determinant of cardiac output, a
lowermaximumHR is thought to impair the ability of the aging
heart to augment cardiac output during exercise.5 The age-
dependent decrease in sensitivity to b-adrenergic stimulation
also directly limits the increase in contractile force in response to
exercise in older adults.41,42,60-62 These changes appear miti-
gated, in part, by an increase in LV end-diastolic volume during
exercise in older adults.5 This produces more blood in the
ventricle at the end of diastole, which through the Frank-
Starling mechanism increases stretch on the heart and the
strength of contraction. Greater reliance on the Frank-Starling
mechanism may at least partially compensate for the lower
HR and reduced contractility of the aging heart during exer-
cise.5 The major structural and functional changes associated
with cardiac aging, along with potential clinical consequences
and important sex differences, are summarized in Table 1.Cellular Mechanisms of Dysfunction in the
Aging Heart
Animal models have yielded evidence for a variety of
molecular mechanisms that contribute to structural and
functional remodelling of the aging heart. A full consideration
of the mechanisms implicated in cardiac aging is beyond this
review’s remit. We focus on altered calcium homeostasis,
chronic systemic activation of the b-adrenergic and renin-
angiotensin pathways, and mitochondrial dysfunction as
likely mechanisms in key aspects of cardiac aging.
Intracellular calcium homeostasis
Cardiac contraction and relaxation reﬂect the rise and fall
of intracellular calcium levels in individual cardiac myocytes.
Age-dependent changes in the regulation of intracellular cal-
cium affect the ability of the heart to contract.23 For example,
smaller calcium transients are responsible for the smaller
contractions observed in ventricular myocytes from aged male
rodents compared with younger animals.24,25 Smaller calcium
transients are thought to arise, in part, from a reduction in
peak calcium currents, leading to less calcium inﬂux in
myocytes from aged male rodents.23 By contrast, age has little
1070 Canadian Journal of Cardiology
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tractions in cells from female rodents and actually enhances
these responses in cells from aged sheep.23,26 The age-
dependent decrease in peak calcium transients/contractions
in myocytes from male animals but not female animals may
help explain why systolic dysfunction and HFrEF are seen
more in older men than in older women.36
Altered calcium homeostasis also helps explain slowed
relaxation and diastolic dysfunction in the aging heart.
Prolongation of relaxation in the aging heart reﬂects a slower
rate of decay of the calcium transient.23 This is clear in older
male animals but less so in older female animals, although few
studies have used female animals.23 Slower calcium transient
decay arises from reduced calcium uptake into stores in the
sarcoplasmic reticulum (SR), resulting from reduced expression
and activity of the SR calciumeadenosine triphosphatase
pump.23 Prolonged availability of internal calcium causes
persistent activation of contractile ﬁlaments, which delays active
ventricular relaxation and compromises LV ﬁlling in early
diastole.10,37 There are additional age-related changes in con-
tractile proteins in both sexes.23 There is a shift from the fast a-
myosin heavy chain isoform to the slower b-isoform with age in
hearts from both sexes, which can slow relaxation.23 These
changes help explain the increase inHFpEF in older adults.37,39
Still, why HFpEF occurs more commonly in women, whereas
outcomes are worse in men, obliges further investigations.
Chronic activation of the b-adrenergic and renin-
angiotensin pathways
Normally, activation of cardiac b-adrenergic receptors in-
creases HR and contractile force, but there is strong evidence
that myocardial responsiveness to b-adrenergic stimulation
declines with age.41 This age-related decline in sensitivity to
catecholamine stimulation has been attributed to high levels of
circulating catecholamines, which lead to chronic activation of
the b-adrenergic pathway in humans and animals.41,42,63
Chronic activation of this pathway arises from reduced
plasma clearance of noradrenaline and increased catechol-
amine spillover into circulation from organs such as the
heart.41 Chronic activation of the b-adrenergic pathway has
been implicated in several aspects of cardiac aging. For
example, chronic b-adrenergic stimulation can damage the
heart by increasing the production of mitochondrial reactive
oxygen species (ROS),10 as discussed in the section Mito-
chondrial Dysfunction. It also can desensitize elements of the
b-adrenergic signalling cascade and limit the increased HR
response seen with changing position or with exercise.41,47
Desensitization of the b-adrenergic pathway in aging also
limits the increase in force normally seen in response to ex-
ercise.41 The underlying mechanisms have not been fully
elucidated, but there is evidence that fewer b-adrenergic re-
ceptors, less cyclic adenosine monophosphate production or
desensitization of other components of the b-adrenergic sig-
nalling pathway (or a combination) play a role.41,42,60-62
Animal studies suggest that circulating catecholamine levels
increase with age to a lesser extent in female animals than in
male animals.42 Although this has not yet been observed in
humans,63 few studies have directly compared older men and
women. Additional studies in humans and animal models
could clarify this issue.Chronic activation of the renin-angiotensin system also is
thought to play a role in cardiac aging. In younger animals,
chronic infusion of angiotensin II causes cardiac hypertrophy,
ﬁbrosis, and slowed relaxation,64 a phenotype that resembles
cardiac aging. Studies have shown that activation of angio-
tensin II type 1 receptors on ﬁbroblasts stimulates ﬁbroblast
proliferation, increases collagen synthesis, and augments the
expression of extracellular matrix proteins.64 Angiotensin II is
also thought to promote growth in adult cardiac myocytes by
inducing the expression of growth factors such as transforming
growth factor b.64 Chronic exposure to angiotensin II also
damages the heart by increasing cellular and mitochondrial
ROS,10 as discussed in the section Mitochondrial Dysfunction.
These similarities between the angiotensin IIetreated heart
and the aging heart suggest that angiotensin II may play a role
in cardiac aging. Indeed, evidence from rodent models has
shown that cardiac angiotensin II levels increase with age, and
this has been linked to hypertrophy, ﬁbrosis, and diastolic
dysfunction in the aging heart.65 Interestingly, the effects of
angiotensin on the aging heart appear to differ between the
sexes. For example, female mice with elevated intracardiac
levels of angiotensin II exhibit age-dependent contractile
depression, whereas male mice do not.66 These ﬁndings
support the concept that the inﬂuence of age on the heart
differs prominently between the sexes.
Mitochondrial dysfunction
The heart is rich in mitochondria that help provide the
energy required for optimal myocardial function. Conversely,
mitochondrial respiration is a major source of ROS produc-
tion, so high levels of these organelles in the heart increase its
risk of oxidative damage.10 Indeed, ROS generation increases
with age in both humans and animals.67,68 The increase in
ROS in the aging heart is similar in the male and female sexes,
at least in animal models.69 It is currently thought that the age-
associated increase in mitochondrial ROS damages mito-
chondrial DNA, which disrupts mitochondrial function,
further increasing ROS production and damaging mito-
chondrial DNA plus other macromolecules.70 This age-
dependent increase in oxidative damage can help explain
mitochondrial dysfunction in the aging heart.70
The key role of ROS generation and mitochondrial
dysfunction in cardiac aging is supported by experiments that
target mitochondrial ROS. For example, overexpression of the
ROS scavenger enzyme catalase attenuates the development of
hypertrophy, ﬁbrosis, and diastolic dysfunction in the aging
mouse heart.65 By contrast, prematurely aging mice with a
mutation in mitochondrial DNA polymerase exhibit marked
cardiac hypertrophy and ﬁbrosis as well as systolic and dia-
stolic dysfunction.71 Together, these observations suggest that
ROS generation and mitochondrial damage contribute to
cardiac aging. Still, the role of ROS accumulation in aging is
controversial because some studies suggest that intracellular
ROS may also have beneﬁcial effects in aging,68 so this re-
mains an active area of research.
Understanding the aging context
Much of the research reviewed here has focused on a small
number of mechanisms in the context of aging changes. Many
studies have only used males of the species in the belief
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The Aging Heart(generally false)72 that the estrus cycle gives too great a degree
of variability for valid conclusions about the impact of age.
Ironically, much less attention has been paid to the well-
recognized variability in degree of age-related changes in an-
imals of the same age,73,74 which is the basis of frailty.75 For
this reason, our group has developed frailty measures for use
in mouse models,43 including 1 that is suitable for longitu-
dinal study.44,76 Preclinical studies in animal models of frailty
may help translate animal work into human treatments.Summary
The incidence of CVD increases with age in both sexes,
although men and women are predisposed toward different
CVDs as they age.36,38 Male/female differences in coronary
artery disease, including a higher risk of obstructive disease in
men and more microvascular disease in women,77 clearly
contribute to sex differences in CVD expression. In addition,
as reviewed here, there are marked age-dependent changes in
the structure and function of the heart that differ between the
sexes. This cardiac remodelling occurs even in healthy older
adults with no signs of overt CVD. Still, whether cardiac
aging itself represents a disease is debated. Sir John Grimley
Evans once said that “to draw a distinction between disease
and normal aging is to attempt to separate the undeﬁned from
the indeﬁnable.”78 More recently, Lakatta argued that cardiac
aging is a disease,79 in part because many of its adverse effects
can be modiﬁed by factors such as changes in diet and exer-
cise. Although the relationship between cardiac aging and
heart disease may be contested, there is little doubt that age-
associated structural and functional changes in the heart
have potentially important clinical consequences, as summa-
rized in Table 1. Table 1 also indicates that many features of
cardiac aging differ between the sexes, although more work in
this area is clearly needed. There is emerging evidence that
frailty may have a major impact on cardiac aging, an idea that
is motivating additional research by our group. An improved
understanding of the mechanisms involved in the effects of
age and frailty on both male and female hearts may help
explain why men and women are susceptible to different
CVDs as they age and may help identify new treatments for
these diseases in both sexes.Acknowledgements
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